Barry is the Vice President of Engineering at BioSig Technologies, Inc., where he is primarily responsible for new product development. He also leads the development of bioelectronic medicine devices for BioSig's subsidiary NeuroClear Technologies, Inc., who, in partnership with the Mayo Clinic, are focused on developing technologies to treat cardiac and neurological conditions by mediating certain neural pathways. He is a Board Member of the Alfred Mann Institute for Biomedical Engineering at USC and is a Steering Committee member of the Alliance for Advancing Bioelectronic Medicine.
Prior to his current role he served as Chief Technology Officer at the Alfred Mann Foundation for Scientific Research, developing implantable neuromodulation devices to treat chronic conditions, and spent 10 years at Medtronic managing an R&D team who developed the first FDA approved artificial pancreas. He has consulted for several neuromodulation device companies, is the inventor on over 40 patents and authored over 30 scientific manuscripts and book chapters.
Barry has a PhD in Biomedical Engineering from the University of Ulster and an MBA from Cornell University. He is a Fellow of the American Institute for Medical and Biological Engineering.
- Bioelectronic Medicine- Redefining Medical Treatment
- Tuesday, February 11 • 2:05 PM - 3:00 PM